Finding affordable healthcare solutions that are effective and reduce or delay CINV
in patients undergoing chemotherapy may make a significant impact on health outcomes and quality of life.
Table 15: Europe Market Size of CINV
in USD, Million (2013-2023)
Since NK1 receptor antagonists are used in combination with 5-HT3 receptor antagonists, CINVANTI offers a strong strategic and operational fit with Heron's existing commercial product, SUSTOL[R], our extended-release, injectable product that incorporates the 5-HT3 receptor antagonist granisetron and is also indicated for the prevention of CINV
3] receptor antagonist, Palonosetron with high receptor binding affinity and long elimination half-life of 40 hours is found to be effective in delayed CINV
is one of the most common side effects of chemotherapy.
for a treatment combining netupitant and palonosetron for the prevention of acute and delayed nausea and vomiting associated with CINV
Being female is the strongest predictor for PONV (27) and CINV
SUSTOL is the first approved therapy that utilises the company's Biochronomer polymer-based drug delivery technology, allowing it to maintain therapeutic levels of granisetron for >=5 days, covering both the acute and delayed phases of CINV
Although paediatric patients were administered a higher dose per kg than adults to prevent CINV
, palonosetron safety profile was consistent with its established profile in adults.
The neurotransmitters in CINV
are dopamine, 5-HT3, substance P, and endocannabinoids.
While this study demonstrated that pediatric patients require a higher palonosetron dose based on weight than adults to prevent CINV
, the safety profile for ALOXI was confirmed as being consistent with the established profile in adults.
Existing & Pipeline Drugs Market: http://www.